Press releases
- Xeris Biopharma Announces CEO Succession Plan
- Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024
- Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121)
- Xeris to Participate in the Jefferies Global Healthcare Conference
- Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events
- Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics
- Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024
More ▼
Key statistics
As of last trade Xeris Biopharma Holdings Inc (2B30:MUN) traded at 2.30, -22.43% below its 52-week high of 2.96, set on Feb 15, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.30 |
---|---|
High | 2.30 |
Low | 2.30 |
Bid | 2.28 |
Offer | 2.38 |
Previous close | 2.21 |
Average volume | 199.33 |
---|---|
Shares outstanding | 148.26m |
Free float | 144.27m |
P/E (TTM) | -- |
Market cap | 376.57m USD |
EPS (TTM) | -0.4648 USD |
Data delayed at least 15 minutes, as of Jul 24 2024 07:00 BST.
More ▼